Bicyclol

Summary

Bicyclol (CHEMBL482035) is a phase-3 clinical-stage small molecule; indicated across 1 condition including injury.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 390.3 Da · C19H18O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL482035
Name	Bicyclol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9821754
Molecular formula	C19H18O9
Molecular weight	390.3
InChIKey	KXMTXZACPVCDMH-UHFFFAOYSA-N

SMILES: COC1=C2C(=C(C(=C1)CO)C3=C4C(=C(C=C3C(=O)OC)OC)OCO4)OCO2

IUPAC name: methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate

Also known as: Bicyclol, bicyclol, BICYCLOL

Patent coverage: 266 distinct patent families (413 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 397 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
injury	3	MONDO:0021178	EFO:0000546

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05711459	Not specified	UNKNOWN	Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).